Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Yen Weakens After Intervention Spike as Dollar Stabilizes Amid Global Tensions 
US Dollar Weakens as Yen Surges Amid Japan Intervention and Central Bank Moves 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Gold Prices Dip Ahead of Fed Decision Amid Rising Middle East Tensions 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
China Factory Activity Extends Growth in April Despite Global Pressures 
Iran-U.S. Conflict Escalation Threatens Global Oil Supply and Economic Stability 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Wall Street Surges to Record Highs Amid Strong Earnings and Economic Stability 
Oil Prices Surge Near $120 as U.S.-Iran Tensions Threaten Global Supply 
Markets Stay Strong Despite Oil Shock Concerns as Earnings Drive Investor Confidence 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Gold Prices Slip Amid Iran Tensions and Rising Rate Concerns 
Celltrion, a South Korean pharmaceutical company, formulated a COVID-19 antibody treatment, and it is reportedly ready to deliver the drug to the United States and Europe. With its new treatment, the company has now made the world’s third drug for coronavirus.
Now it is likely to enter the European and U.S. markets before this year ends, as per The Korea Herald. This information was revealed in a report that was released on Monday, Aug. 23.
Lee Dong Geon, an analyst at Shinhan Investment, said that Celltrion will be applying for the issuance of emergency use authorization for its Regkirona COVID-19 antibody treatment. It is hoped that the US Food and Drug Administration will approve this drug that is also called the CT-P59 for EUA.
Moreover, it was predicted that it would not be long until Celltrion’s Regkirona is approved. In fact, it may be out in the U.S. market as early as the fourth quarter of this year. As for the EU market, it was estimated that it could obtain regulatory approval from the Europen Medicine Agency before October since it is already under review.
Apparently, once Celltrion succeeded in rolling out Regkirona in the U.S. and Europe, the company’s position in the pharmaceutical business will surely improve, and this will be felt and observed in the coming months.
In any case, Rekirona is an antibody treatment for coronavirus, and it is the first drug to be developed by Celltrion. It already received a green light from South Korea, Indonesia, and recently, in Brazil. The pharma firm said that as soon as the EMA gives its approval, it will immediately ship the drug to the EU.
Celltrion said that this treatment could shorten the number of treatment days for patients with COVID-19. What’s more, it could also prevent the condition of patients from getting severe.
Meanwhile, as soon as the news of Celltrion’s possible shipment of Regkirona to major markets in the world, Pulse News reported that the company’s shares soared, gaining 6.77 percent to close at ₩284,000 or around $241.97 on Kospi. It was added that it finished 8.21 percent higher and Celltrion Healthcare also went up by 7.94 percent.
